The newly formed research group on vaccinations meeting for the very first time this week at the US National Institutes of Health (NIH) wanted its members to be able to make their work easier.
Nonetheless, they are charged with performing human trials for emerging threats–and their first assignment was a surprising one.
The first of a number of potential research vaccines against the latest coronavirus of SARS that spreads in China and beyond are expected to be tested within only three months.
The outbreak, which started with more than 800 people in China in the central Chinese city of Wuhan in December, killed 26 people.
The genetic sequence of the new coronavirus could be quickly identified and published publicly in a couple of days, which allowed research teams to work immediately.
Scientists can begin the development of the vaccine without needing a virus sample with the genetic code in hand.
It took American scientists 20 months to go from the generational transition to the first step of human trials during the deadly 2003 Severe Acute Respiratory Syndrome (SARS) outbreak. The outbreak was monitored at that time.
Research groups worldwide have already been introducing proposals to study vaccinations, therapies and other countermeasures to avoid a global outbreak of the newly identified virus.
Some steps have been taken
We strike from various angles and hope for at least one cure in human studies within a couple of months by the World Health and Epidemic Agencies.
Agency Fauci is in partnership with US Biotech Moderna Inc., a chemical messenger with instructions on protein production based ribonucleic acid (RNA) vaccine.
The team hopes to make an ANR vaccine based on one of the coronavirus-like spikes in the air, which gives the family its name, which would not expose people to the virus, unlike many vaccines.
The findings of laboratory tests for other deadly viruses, including Ebola and coronavirus, have already been positive. This is causing Middle East Respiratory Syndrome (MERS)—a relative of SARS and Wuhan virus.
Novavax, which already has a MERS vaccine, says it is currently working on the Wuhan coronavirus.
Infection-fights proteins known as monoclonal antibodies or mAbs, developed for the treatment of scars and MERS coronaviruses, have also been used by scientists.